Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03528902 · ClinicalTrials.gov registry record · Phase 2
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT03528902 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT03528902, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The main purpose of this clinical trial is to examine the feasibility and effects of tamoxifen in subjects with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated, and its impact on functional condition and selected biomarkers. Changes in tricuspid annular plane systolic excursion (TAPSE) and other parameters determined by transthoracic echocardiography will be evaluated as well as changes in additional metrics such as six minute walk test distance, quality of life assessments, and hormone levels.
Interventions
- DRUG Tamoxifen
- DRUG Placebo Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03528902
The ClinicalTrials.gov registry entry for NCT03528902 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.
NCT03528902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03528902 about?
NCT03528902 is a clinical study titled "Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension". The main purpose of this clinical trial is to examine the feasibility and effects of tamoxifen in subjects with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated, and its impact on functional condition and selected biomarkers. Changes in tricuspid annular ...
What is the current status of trial NCT03528902?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2018-10-01. Estimated completion is 2023-06-14.
What interventions are being tested in trial NCT03528902?
The interventions under investigation include: Tamoxifen (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03528902?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.